Neurocrine Biosciences' Soleno Therapeutics Announces Late-Breaking Data At ENDO 2026 Showing Two Years Of VYKAT XR After 16‑Week Withdrawal Sustained Improvements In Hyperphagia And Behavioral Symptoms In PWS

Neurocrine Biosciences, Inc.

NBIX

0.00

Participants who resumed VYKAT XR following a 16-week randomized withdrawal period demonstrated improvements in hyperphagia and behavioral symptoms as early as Week 13, with benefits continuing through 2 years
VYKAT XR demonstrated statistically significant and sustained improvements in hyperphagia and Prader-Willi syndrome-related behaviors for up to 3 years compared to real-world data from the PATH for PWS Natural History Study

SAN DIEGO, June 15, 2026 /PRNewswire/ -- Soleno Therapeutics, a Neurocrine Biosciences (NASDAQ:NBIX) company, today announced late-breaking data at ENDO 2026 showing that resuming treatment with VYKAT® XR (diazoxide choline) extended-release tablets for two years after a 16-week randomized withdrawal period was associated with durable improvements in hyperphagia and behavioral symptoms characteristic of Prader-Willi syndrome (PWS).

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.